Eylea® 8mg

Aflibercept 8mg Real-World-Evidence and the latest results from Phase II/III

^{Updated: 05.02.2026}

Title	Description	Author	Indication	Congress	Year	Theme
Real-World Outcomes of Switching to Aflibercept 8mg in Eyes with Neovascular Age-Related Macular Degeneration – data from Australia and Europe	Link	Gillies et al.	nAMD	EURETINA	2025	8mg RWE
Early Real-World Outcomes of Aflibercept 8mg in Treatment-naïve Age-Related Macular Degeneration: A Swiss Retina Research Network Report	Link	Ambresin et al.	nAMD	EURETINA	2025	8mg RWE
Real-world outcomes of Aflibercept 8 mg in previously treated neovascular AMD patients	Link	Ishkheidedem et al.	nAMD	EURETINA	2025	8mg RWE
Early real-world efficacy and safety of aflibercept 8mg in Australian patients with neovascular age-related macular degeneration: interim report from the CUREOS research network.	Link	Chang et al.	nAMD	EURETINA	2025	8mg RWE
Early Real-Life Experience with Aflibercept 8mg in switcher patients suffering from neovascular age-related macular degeneration – A Swiss Retina Research Network Report	Link	Ebneter et al.	nAMD	EURETINA	2025	8mg RWE
Clinical experience of switching to aflibercept 8mg in patients with neovascular age-related macular degeneration (nARMD) who did not meet extension treat and extend criteria with different anti-vascular endothelial growth factor (anti-VEGF) agents	Link	Papadakis et al.	nAMD	EURETINA	2025	8mg RWE
Early Real-Life Experience with Aflibercept 8mg in Diabetic Macular Edema – a Swiss Retina Research Network Report	Link	Garweg et al.	DME	EURETINA	2025	8mg RWE
Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial Intelligence	Link	Bartolomeo et al.	wAMD	EURETINA	2025	8mg RWE
Aflibercept 8 mg in diabetic macular edema: 156-Week results from the PHOTON extension study	Link	Sivaprasad et al.	DME	EURETINA	2025	8mg RCT/Phase-3
Baseline Characteristics and Outcomes of Patients Treated with Aflibercept 8 mg at Shortened, Maintained, or Extended Dosing Intervals through 96 Weeks in PHOTON	Link	Varma et al.	DME	EURETINA	2025	8mg RCT/Phase-3
Clinical Experience with Aflibercept 8 mg in High Need Treatment-Experienced Patients with Neovascular Age-Related Macular Degeneration	Link	Mojumder et al.	nAMD	ARVO	2025	8mg RWE
Comparison of Aflibercept 8mg and Bevacizumab Treatment Intervals at a Large Single-Specialty Retina Practice	Link	Kumar et al.	nAMD / DME	ARVO	2025	8mg RWE
Differential Anatomic Response to Aflibercept 8 mg Versus 2 mg During the Matched Dosing Phase of the PHOTON Trial in Patients With Diabetic Macular Edema Who Subsequently Met Criteria for Shortening	Link	Goldberg et al.	DME	EURETINA	2025	8mg RCT/Phase-3
Early insights from real-world use of aflibercept 8 mg among eyes with neovascular age-related macular degeneration (nAMD) switching from other anti-VEGF agents	Link	Leng et al.	nAMD	ARVO	2025	8mg RWE
Early insights from real-world use of aflibercept 8 mg among eyes with diabetic macular edema (DME) switching from other anti-VEGF agents	Link	Javaheri et al.	DME	ARVO	2025	8mg RWE
Early Insights from Real-world use of Aflibercept 8 mg Among Eyes with Diabetic Macular Edema Switching from Other Anti-VEGF Agents	Link	Midena et al.	DME	EURETINA	2025	8mg RWE
Early insights on the real-world use of aflibercept 8 mg among treatment-naive eyes with diabetic macular edema	Link	Mehta et al.	DME	ARVO	2025	8mg RWE
Early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macular degeneration	Link	Ali et al.	nAMD	ARVO	2025	8mg RWE
Effects of three intravitreal injections of aflibercept 8 mg on ocular circulation in eyes with neovascular age-related macular degeneration	Link	Mizukami et al.	nAMD	ARVO	2025	8mg RWE
Efficacy and Safety of Aflibercept 8mg in Treating Diabetic Macular Oedema: Real World Data	Link	Bedan et al.	DME	ARVO	2025	8mg RWE
Efficacy and safety of three-monthly loading doses of intravitreal injections of Aflibercept 8 mg in clinical practice at a district general hospital in the United Kingdom	Link	Gondal et al.	nAMD	ARVO	2025	8mg RWE
Faricimab versus Aflibercept 8mg in the Treatment of Eyes Recalcitrant to Alternative Anti-VEGF Therapies	Link	Chang et al.	nAMD / DME	ARVO	2025	8mg RWE
Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in neovascular age-related macular degeneration (nAMD)	Link	Bala et al.	nAMD	ARVO	2025	8mg RWE
Pigment epithelial detachment outcomes with aflibercept 8 mg versus aflibercept 2 mg in the PULSAR trial: A 96-week post hoc analysis	Link	Singer et al.	nAMD	EURETINA	2025	8mg RCT/Phase-3
PULSAR Extension Phase: Fluid resolution over 156 weeks in patients with neovascular age-related macular degeneration receiving aflibercept 8 mg and in patients switching from aflibercept 2 mg to 8 mg	Link	Munk et al.	nAMD	EURETINA	2025	8mg RCT/Phase-3
PULSAR Extension: Clinical improvements sustained over 156 weeks with aflibercept 8 mg in patients with neovascular age-related macular degeneration	Link	Ambresin et al.	nAMD	EURETINA	2025	8mg RCT/Phase-3
PULSAR Extension: Clinical improvements through 156 weeks with aflibercept 8 mg in patients with choroidal neovascularization and polypoidal choroidal vasculopathy	Link	Chen et al.	nAMD	EURETINA	2025	8mg RCT/Phase-3
PULSAR Extension: Comparable clinical outcomes with lower treatment burden over 156 weeks in patients with neovascular age-related macular degeneration who switch from aflibercept 2 mg to aflibercept 8 mg	Link	Zweifel et al.	nAMD	EURETINA	2025	8mg RCT/Phase-3
PULSAR Extension: Intraocular inflammation-related events with aflibercept 8 mg through 156 weeks in patients with neovascular age-related macular degeneration	Link	Souied et al.	nAMD	EURETINA	2025	8mg RCT/Phase-3
PULSAR Extension: Safety analysis of aflibercept 8 mg through 156 weeks in patients with neovascular age-related macular degeneration	Link	Khoramnia et al.	nAMD	EURETINA	2025	8mg RCT/Phase-3
Real-world efficacy, safety, and durability of aflibercept 8 mg in neovascular age-related macular degeneration	Link	Donia et al.	nAMD	ARVO	2025	8mg RWE
Real-World Outcomes of Patients Switching to Aflibercept 8 mg: An AI-Powered retrospective Analysis	Link	Zhang et al.	nAMD / DME	EURETINA	2025	8mg RWE
Résultats anatomiques précoces des injections intravitréennes d'aflibercept 8 mg chez les patients atteints de dégénérescence maculaire liée à l'âge néovasculaire récidivante	Link	Ambresin et al.	nAMD	SFO	2025	8mg RWE
Similar visual and anatomic outcomes with aflibercept 8 mg in patients with neovascular age-related macular degeneration as defined by baseline BCVA and CRT: A 156-week PULSAR subgroup analysis	Link	Kodjikian et al.	nAMD	EURETINA	2025	8mg RCT/Phase-3
SPECTRUM: Early clinical experience in the first global real-world study of aflibercept 8 mg in patients with treatment-naive diabetic macular edema	Link	Lanzetta et al.	nAMD	EURETINA	2025	8mg RWE
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with treatment-naïve neovascular age-related macular degeneration	Link	Konidaris et al.	nAMD / DME	ARVO	2025	8mg RWE
SPECTRUM: Early clinical outcomes in the first global real-world study of aflibercept 8 mg in patients with previously treated diabetic macular edema	Link	Chaudhary et al.	DME	EURETINA	2025	8mg RWE
SPECTRUM: Early clinical outcomes in the first global real-world study of aflibercept 8 mg in patients with treatment-naive neovascular age-related macular degeneration	Link	Bailey et al.	nAMD	EURETINA	2025	8mg RWE
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with pretreated neovascular age-related macular degeneration	Link	Bailey et al.	nAMD / DME	ARVO	2025	8mg RWE
SPECTRUM: Month 6 results from the first global real-world study of aflibercept 8 mg in patients with previously treated neovascular age-related macular degeneration	Link	Stahl et al.	nAMD	EURETINA	2025	8mg RWE
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with treatment-naïve diabetic macular edema	Link	Lobo et al.	nAMD / DME	ARVO	2025	8mg RWE
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with pretreated diabetic macular edema	Link	Dervos et al.	nAMD / DME	ARVO	2025	8mg RWE
Week 96 outcomes in aflibercept 8 mg- and 2 mg-treated patients by prior DME treatment status: a subgroup analysis of the Phase 2/3 PHOTON trial	Link	Udaondo et al.	DME	EURETINA	2025	8mg RCT/Phase-3
Real-World Functional and Anatomical Outcomes of High-Dose Aflibercept 8.0 mg in Diabetic Macular Edema	Link	Barbosa et al.	DME	ARVO	2025	8mg RWE
The Effect of Using High Dose Aflibercept 8mg in Treating Age-Related Macular Degeneration	Link	Gartaganis et al.	nAMD	ARVO	2025	8mg RWE
Real World Experience of Aflibercept 8mg at York and Scarborough Teaching Hospitals NHS Foundation trust for neovascular Age related Macula Degeneration (nAMD) and Diabetic Macular Edema (DME).	Link	Anakwenze et al.	nAMD / DME	ARVO	2025	8mg RWE
Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series	Link	Sambhara et al.	nAMD	ARVO	2025	8mg RWE
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with pretreated neovascular age-related macular degeneration	Link	Bailey et al.	nAMD / DME	ARVO	2025	8mg RWE / Presentation
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with treatment-naïve neovascular age-related macular degeneration	Link	Konidaris et al.	nAMD / DME	ARVO	2025	8mg RWE / Presentation

Loading ...